The RAMPP study aims to investigate the use of a pleural vent (rocket) versus standard care in patients with Primary Spontaneous Pnuemothorax in a randomised controlled trial.
1. Presenting with primary spontaneous pneumothorax as confirmed by a chest radiograph or a CT scan.
2. Age >= 18 years old and <= 55 years old.
3. Ability to consent to participation.
1. Known or suspected underlying lung disease (including >20 pack year smoking history).
2. Evidence of tension pneumothorax (these patients should be treated immediately as medical emergencies).
3. Females who are pregnant or lactating.
4. Inability to consent or comply with the trial requirements.
5. Contraindication to thoracic procedure. (Only applies to patients being enrolled into Intervention or Control arms – i.e. not observational cohort).
6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
Funding: Medical Research Council and the National Institute for Health Research (UK).
Sponsor: University of Oxford, Churchill Hospital (UK)
Setting: This is a multi-centre study being co-ordinated from Oxford.
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions